Home World News FDA Approves Acalabrutinib with Venetoclax for CLL or SLL World News FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 389 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 Closing the gap: How new screening interventions could reduce inequalities in... July 5, 2022 Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion... July 7, 2022 EMA Recommends Extension of Therapeutic Indications for Cetuximab August 14, 2026 Load more HOT NEWS Binimetinib Contributes to the Efficacy and Safety Outcomes Observed with Encorafenib... Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated...
